A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Dopamine acts through five receptor subtypes (D1–D5) that couple to different G-protein pathways: D1/D5 activate Gs (increasing cAMP), while D2/D3/D4 activate Gi (decreasing cAMP). D1 and D2 receptors have distinct anatomical distributions—D1 predominates in striatal direct pathway neurons (facilitating movement), while D2 is enriched in indirect pathway neurons (inhibiting movement). This complementary arrangement enables dopamine to coordinate motor output and reward-motivated behavior.
Map D1 and D2 receptor distribution across striatal neurons using immunohistochemistry. Apply selective D1 or D2 agonists/antagonists and observe motor and motivational changes to understand functional dissociability.
Dopamine does not simply 'reward'; D2 activation can suppress movement through indirect pathway activation. Dopamine receptors are not equally distributed—D1 vs D2 balance within local circuits is functionally critical.
You already know that dopamine is a key neurotransmitter in reward circuitry and that receptors couple to G-proteins to transduce signals inside cells. Now we can zoom in: dopamine does not just "arrive and signal reward." What it does depends entirely on which receptor it binds and where in the brain that receptor lives. The five receptor subtypes split cleanly into two families. D1-class receptors (D1 and D5) couple to Gs proteins, which activate adenylyl cyclase and raise intracellular cAMP. D2-class receptors (D2, D3, D4) couple to Gi proteins, which inhibit adenylyl cyclase and lower cAMP. The downstream consequences of raising versus lowering cAMP in a neuron are dramatically different — higher cAMP generally increases excitability and gene transcription through PKA, while lower cAMP dampens these effects.
The anatomical distribution of D1 and D2 receptors is not random — it maps precisely onto the two output pathways of the striatum, which is the input nucleus of the basal ganglia. Striatal neurons that project through the direct pathway (to the globus pallidus interna and substantia nigra pars reticulata) predominantly express D1 receptors. When dopamine activates these D1 neurons, cAMP rises, these neurons become more active, and movement is facilitated. Striatal neurons that project through the indirect pathway (through the external pallidum and subthalamic nucleus) predominantly express D2 receptors. When dopamine activates D2 receptors on these neurons, cAMP falls, indirect-pathway activity decreases, and the net effect is also to facilitate movement by releasing the brake on the thalamus. Both pathways are thus pushed in a pro-movement direction by dopamine, but through opposite receptor mechanisms on opposite cell populations.
This dual-pathway architecture explains a classic clinical puzzle. Parkinson's disease involves the degeneration of dopamine neurons projecting from the substantia nigra to the striatum. Losing dopamine means D1-pathway neurons are underactivated and D2-pathway neurons lose their inhibition — together producing the hallmark bradykinesia and rigidity of Parkinson's. L-DOPA treatment replenishes dopamine and restores the balance. But it also explains why too much dopamine (or drugs that mimic it) produces hyperkinetic disorders like tardive dyskinesia. The system is tuned to a set point; deviation in either direction produces pathology.
The D2 receptor is also the primary target of antipsychotic medications. First-generation antipsychotics (haloperidol, chlorpromazine) are potent D2 antagonists, and their efficacy against positive symptoms of schizophrenia was a major clue that excess D2 signaling contributes to psychosis. Unfortunately, D2 blockade in the striatal motor circuits produces extrapyramidal side effects — drug-induced Parkinsonism — which is the predictable consequence of eliminating dopamine's pro-movement effect on the direct pathway. Second-generation antipsychotics have a lower D2 affinity and higher serotonin receptor affinity, reducing (but not eliminating) these motor side effects. The receptor subtype distribution thus links molecular pharmacology directly to clinical neurology and psychiatry.